Evidence map›Paper›PMID 42669706›Full record

ArticleNaunyn-Schmiedeberg's archives of pharmacology2026

Cyclodextrin nanosponges enhance the oral pharmacokinetics and antiplatelet efficacy of prasugrel hydrochloride in Wistar rats.

Atul Suryawanshi, Mukesh Ratnaparkhi, Rushikesh Shinde

Abstract read
PubMed Publisher
In one paragraph

Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Atul SuryawanshiDepartment of Pharmaceutics, Marathwada Mitra Mandal's College of Pharmacy, Affiliated to Savitribai Phule Pune University, Thergaon (Kalewadi), Pune, 411033, Maharashtra, India.ORCID http://orcid.org/0009-0008-5745-0762
Mukesh RatnaparkhiDepartment of Pharmaceutics, Marathwada Mitra Mandal's College of Pharmacy, Affiliated to Savitribai Phule Pune University, Thergaon (Kalewadi), Pune, 411033, Maharashtra, India. mukeshparkhi@yahoo.co.in.ORCID http://orcid.org/0000-0003-0446-4243
Rushikesh ShindeDepartment of Pharmaceutics, Marathwada Mitra Mandal's College of Pharmacy, Affiliated to Savitribai Phule Pune University, Thergaon (Kalewadi), Pune, 411033, Maharashtra, India.ORCID http://orcid.org/0009-0003-0304-3057

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The present study aimed to evaluate the pharmacokinetic and pharmacodynamic performance of an optimized prasugrel hydrochloride-loaded nanosponge formulation (PSG-NS) following oral administration and to compare its systemic exposure and antiplatelet efficacy with a marketed prasugrel tablet formulation. PSG-NS was orally administered to male Wistar rats at a dose equivalent to 5 mg/kg and compared with a marketed prasugrel tablet suspension (Prasita®). Plasma concentrations were quantified using an RP-HPLC-UV method and analyzed using non-compartmental and compartmental pharmacokinetic approaches. Pharmacodynamic efficacy was evaluated using ADP-induced platelet aggregation and a ferric chloride-induced carotid artery thrombosis model. The PSG-NS formulation demonstrated significantly enhanced systemic exposure compared with Prasita®. PSG-NS achieved a significantly higher C

Indexed as

Antiplatelet activityCyclodextrin nanospongesOral drug deliveryPharmacokineticsPK–PD relationshipPlatelet aggregationPrasugrel

Identifiers

PMID42669706

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.